Retroperitoneal vs. transperitoneal robotic partial nephrectomy: a multicenter propensity-score matching analysis (PADORA Study - UroCCR n° 68).


Journal

Minerva urology and nephrology
ISSN: 2724-6442
Titre abrégé: Minerva Urol Nephrol
Pays: Italy
ID NLM: 101777299

Informations de publication

Date de publication:
Aug 2023
Historique:
medline: 3 8 2023
pubmed: 2 8 2023
entrez: 2 8 2023
Statut: ppublish

Résumé

Robot-assisted partial nephrectomy can be performed through either a transperitoneal or retroperitoneal approach. This study aimed to compare the rate of trifecta achievement between retroperitoneal (RRPN) and transperitoneal (TRPN) robot-assisted partial nephrectomy using a large multicenter prospectively-maintained database and propensity-score matching analysis. This study was launched by the French Kidney Cancer Research Network, under the UroCCR Project (NCT03293563). Patients who underwent TRPN or RRPN by experienced surgeons in 15 participating centers were included. Data on demographic and clinical parameters, tumor characteristics, renal function, and surgical parameters were collected. The primary outcome was the rate of trifecta achievement, which was defined as a warm ischemia time of less than 25 minutes, negative surgical margins, and no major complications. Secondary outcomes included operative time, hospital length-of-stay, blood loss, postoperative complications, postoperative renal function, and each trifecta item taken alone. Subgroup analysis was done according to tumor location. A total of 2879 patients (2581 TRPN vs. 298 RRPN) were included in the study. Before matching, trifecta was achieved in 73.0% of the patients in the TRPN group compared to 77.5% in the RRPN group (P=0.094). After matching 157 patients who underwent TRPN to 157 patients who underwent RRPN, the trifecta rate was 82.8% in the TRPN group vs. 84.0% in the RRPN group (P=0.065). The RRPN group showed shorter operative time (123 vs. 171 min; P<0.001) and less blood loss (161 vs. 293 mL; P<0.001). RRPN showed a higher trifecta achievement for posterior tumors than TRPN (71% vs. 81%; P=0.017). RRPN is a viable alternative to the transperitoneal approach, particularly for posterior renal tumors, and is a safe and effective option for partial nephrectomy.

Sections du résumé

BACKGROUND BACKGROUND
Robot-assisted partial nephrectomy can be performed through either a transperitoneal or retroperitoneal approach. This study aimed to compare the rate of trifecta achievement between retroperitoneal (RRPN) and transperitoneal (TRPN) robot-assisted partial nephrectomy using a large multicenter prospectively-maintained database and propensity-score matching analysis.
METHODS METHODS
This study was launched by the French Kidney Cancer Research Network, under the UroCCR Project (NCT03293563). Patients who underwent TRPN or RRPN by experienced surgeons in 15 participating centers were included. Data on demographic and clinical parameters, tumor characteristics, renal function, and surgical parameters were collected. The primary outcome was the rate of trifecta achievement, which was defined as a warm ischemia time of less than 25 minutes, negative surgical margins, and no major complications. Secondary outcomes included operative time, hospital length-of-stay, blood loss, postoperative complications, postoperative renal function, and each trifecta item taken alone. Subgroup analysis was done according to tumor location.
RESULTS RESULTS
A total of 2879 patients (2581 TRPN vs. 298 RRPN) were included in the study. Before matching, trifecta was achieved in 73.0% of the patients in the TRPN group compared to 77.5% in the RRPN group (P=0.094). After matching 157 patients who underwent TRPN to 157 patients who underwent RRPN, the trifecta rate was 82.8% in the TRPN group vs. 84.0% in the RRPN group (P=0.065). The RRPN group showed shorter operative time (123 vs. 171 min; P<0.001) and less blood loss (161 vs. 293 mL; P<0.001). RRPN showed a higher trifecta achievement for posterior tumors than TRPN (71% vs. 81%; P=0.017).
CONCLUSIONS CONCLUSIONS
RRPN is a viable alternative to the transperitoneal approach, particularly for posterior renal tumors, and is a safe and effective option for partial nephrectomy.

Identifiants

pubmed: 37530660
pii: S2724-6051.23.05346-6
doi: 10.23736/S2724-6051.23.05346-6
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

434-442

Commentaires et corrections

Type : CommentIn

Auteurs

Georges Mjaess (G)

Department of Urology, Brussels University Hospital, Brussels, Belgium - gmjaess@gmail.com.

Jean-Christophe Bernhard (JC)

Department of Urology, CHU Bordeaux, Bordeaux, France.

Zine-Eddine Khene (ZE)

Department of Urology, CHU Rennes, Rennes, France.

Nicolas Doumerc (N)

Department of Urology, CHU Toulouse, Toulouse, France.

Christophe Vaessen (C)

Department of Urology, Hôpital La Pitié Salpétrière, Paris, France.

François Henon (F)

Department of Urology, CHU Lille, Lille, France.

Franck Bruyere (F)

Department of Urology, CHU Tours, Tours, France.

Martin Brenier (M)

Department of Urology, Hôpital Saint Joseph, Paris, France.

Bastien Parier (B)

Department of Urology, Hôpital Kremlin Bicêtre, Paris, France.

Simone Albisinni (S)

Department of Urology, Brussels University Hospital, Brussels, Belgium.
Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy.

Alexandre Ingels (A)

Department of Urology, CHU Henri Mondor, Créteil, France.
Inserm, Clinical Investigation Center 1430, Henri Mondor University Hospital, AP-HP, Creteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH